APMI and APMI-CP (International Level)
President and Founding Director: H. Hampel, MD, PhD, MSc
Vice-President and Scientific Director: S. Lista, PhD
Clinical Director and Deputy Scientific Director: A. Vergallo, MD
The Precision Medicine strategy is assumed to facilitate a paradigm shift from the traditional “one-size-fits-all” approach in drug discovery towards biomarker-guided “tailored” therapies, i.e. targeted and timed interventions adapted to the biological profile of the individual patients: the right drug, for the right patients, at the right time.
In this context, the U.S. Precision Medicine Initiative (PMI) (https://obamawhitehouse.archives.gov/precision-medicine) and the U.S. “All of Us Research Program” (https://allofus.nih.gov/) – have been successfully developed.
During the last decade, large-scale exploratory blood-based biomarker studies indicate pathophysiological commonalities between Alzheimer’s Disease and several oncological / immunological diseases including genetic-epigenetic mechanisms, intracellular signaling, and protein expression profiles. Therefore, successful cross-fertilization between advanced medical research fields, including oncology and immunology, and neurology offers unique opportunities to open new therapeutic discovery and development perspectives for Alzheimer’s Disease.
In order to advance the development of the Precision Medicine paradigm in Alzheimer’s Disease, we have recently launched the Alzheimer Precision Medicine Initiative (APMI), a consortium conceptually linked to the U.S. “All of Us Research Program”.
At the Institute of Memory and Alzheimer’s Disease (IM2A) Pitié-Salpêtrière University Hospital in Paris, a “cohort” of 1,000 participants has been recruited, including cognitively intact older individuals at risk for Alzheimer’s Disease and patients with other neurodegenerative diseases that are part of observational and clinical studies. The variety of multidimensional data collected represents a pilot cohort program that will be the founder and the initiation of the larger international Alzheimer Precision Medicine Initiative-Cohort Program (APMI-CP).